E3 PreliminaryPreliminaryPEM not requiredObservationalPeer-reviewedMachine draft
Neuroactive steroids and fatigue severity in patients with primary biliary cirrhosis and hepatitis C.
Ahboucha, S, Butterworth, R F, Pomier-Layrargues, G et al. · Neurogastroenterology and motility · 2008 · DOI
Quick Summary
This study looked at whether certain brain chemicals called neuroactive steroids might explain why people with liver disease feel extremely tired. Researchers measured these chemicals in patients with two types of liver disease and compared them to healthy people. They found that patients with liver disease had higher levels of these chemicals, and those with the most fatigue had the highest levels.
Why It Matters
This study identifies a potential shared biological mechanism linking liver disease fatigue to ME/CFS, where similar neuroactive steroid elevations have been previously documented. Understanding whether neuroinhibitory steroid accumulation contributes to ME/CFS fatigue could open new diagnostic and therapeutic avenues for a symptom that affects nearly all ME/CFS patients.
Observed Findings
- Fatigue Impact Scale scores were significantly higher in PBC and CHC patients compared to controls (P < 0.01).
- 3alpha,5alpha-THP and 3alpha,5beta-THP plasma levels were significantly elevated in both PBC and CHC patients.
- 3alpha,5alpha-THP and 3alpha,5beta-THP were significantly higher specifically in fatigued patients compared to non-fatigued patients (P < 0.05).
- Other progesterone metabolites tested were either undetectable or present only in some patients.
- Non-fatigued liver disease patients had steroid levels not significantly different from controls.
Inferred Conclusions
- Accumulation of GABA-A receptor-active neuroactive steroids may represent a pathophysiological mechanism of fatigue in chronic liver diseases.
- Increased neuroinhibition through GABA-A receptors may underlie fatigue symptoms in patients with elevated 3alpha,5alpha-THP and 3alpha,5beta-THP.
- The association between specific neuroactive steroids and fatigue severity suggests a potential biomarker for fatigue in chronic liver disease.
Remaining Questions
- Do elevated neuroactive steroids directly impair CNS function in fatigued patients, or is the association merely correlational?
- Are the same neuroactive steroid elevation patterns present in ME/CFS patients, and do levels correlate with fatigue severity in that population?
What This Study Does Not Prove
This study does not prove that neuroactive steroids cause fatigue in ME/CFS or that the mechanism operates identically across different diseases. It is a small, preliminary cross-sectional correlation study in liver disease patients and does not establish causation or test whether reducing these steroids would improve fatigue. Generalizability to ME/CFS requires direct replication in ME/CFS populations.
Tags
Symptom:Fatigue
Biomarker:MetabolomicsBlood Biomarker
Method Flag:Weak Case DefinitionSmall SampleExploratory Only
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →